NCCM
RIGL icon

Nine Chapters Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Nine Chapters Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,000
Closed -$27K – 172
2017
Q2 		$27K Buy
+1,000
New +$27.4K 0.26% 52
2015
Q4 		– Sell
-1,700
Closed -$42K – 450
2015
Q3 		$42K Sell
1,700
-370
-18% -$11K ﹤0.01% 947
2015
Q2 		$66K Sell
2,070
-5,790
-74% -$221K 0.01% 899
2015
Q1 		$281K Buy
+7,860
New +$216K 0.02% 736

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nine Chapters Capital Management's RIGL Position: Q3 2017 in Review

Nine Chapters Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2017, closing a stake of 1,000 shares — an estimated $27K sold.

Nine Chapters Capital Management first reported a position in RIGL in Q1 2015 and held it in 4 quarters. The position peaked at $281K in Q1 2015. 108 funds tracked by Wall St. Rank hold RIGL as of Q3 2017.

  • Nine Chapters Capital Management reported no remaining Rigel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 1,000 Rigel Pharmaceuticals shares in Q3 2017, an estimated $27K.
  • Nine Chapters Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Nine Chapters Capital Management's Rigel Pharmaceuticals position peaked at $281K in Q1 2015.
  • 108 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.